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Abstract
Peptides containing the asparagine-glycine-arginine (NGR) motif are recognized by CD13/
aminopeptidase N (APN) receptor isoforms that are selectively overexpressed in tumor neo-
vasculature. Spontaneous decomposition of NGR peptides can result in isoAsp derivatives,
which are recognized by RGD-binding integrins that are essential for tumor metastasis. Pep-
tides binding to CD13 and RGD-binding integrins provide tumor-homing, which can be
exploited for dual targeted delivery of anticancer drugs. We synthesized small cyclic NGR
peptide–daunomycin conjugates using NGR peptides of varying stability (c[KNGRE]-NH2,
Ac-c[CNGRC]-NH2 and the thioether bond containing c[CH2-CO-NGRC]-NH2, c[CH2-CO-
KNGRC]-NH2). The cytotoxic effect of the novel cyclic NGR peptide-Dau conjugates were
examined in vitro on CD13 positive HT-1080 (human fibrosarcoma) and CD13 negative HT-
29 (human colon adenocarcinoma) cell lines. Our results confirm the influence of structure
on the antitumor activity and dual acting properties of the conjugates. Attachment of the
drug through an enzyme-labile spacer to the C-terminus of cyclic NGR peptide resulted in
higher antitumor activity on both CD13 positive and negative cells as compared to the
branching versions.
Introduction
Most of the currently used anticancer drugs have several shortcomings including poor bio-
availability or lack of selectivity, which can result in serious side effects even at therapeutic
doses. To reduce the non-specific cytotoxicity of neoplastic agents, targeted drug delivery
systems may be used, in which the active compound is conjugated to a homing device. Hom-
ing may be mediated by proteins (e.g. antibodies) or peptides (e.g. hormone peptides) that
recognize tumors with high specificity. The concept of selective drug targeting is based on
the high expression of certain cell surface components on tumors or the tumor neovasculature
[1]. It is well known that solid tumors recruit new blood vessels to support tumor growth,
therefore tumor angiogenic vessels might also be used clinically to develop better targeted ther-
apy [2]. One of the cancer specific receptors is aminopeptidase N (APN or CD13). APN is a
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membrane-bound metalloprotease, which can be found not only in tumors and angiogenic
blood vessels, but it is also expressed in various normal cell types (e.g., liver, prostate, kidney,
renal). However, experiments with APN antibodies have shown that different APN isoforms
are expressed in cancer associated endothelial cells and in healthy tissues and blood vessels [3].
Since APN plays a key role in angiogenesis, cell invasion and cell proliferation, it is considered
an ideal target for selective anticancer drug delivery systems [4,5]. The relevance of APN
ligands (NGR (Asn-Gly-Arg) sequence containing peptides) in tumor targeting was discovered
in in vitro screens using phage-display libraries set up to identify non-RGD (-Arg-Gly-Asp-)
integrin binding motives [6–8]. Later, it was shown that NGR peptides bind to a CD13 iso-
form, which is expressed in tumor blood vessels where it functions as a vascular receptor for
the NGR motif containing extracellular matrix (ECM) proteins [3]. The NGR motif is prone to
non-enzymatic deamidation through succinimide ring formation followed by hydrolysis,
resulting in aspartyl and isoaspartyl (DGR and isoDGR) derivatives. Studies have shown that
the formed isoaspartyl (isoDGR) derivative is the ligand of RGD-integrins, which are essential
for tumor angiogenesis, cell invasion and metastasis [9]. Through NGR-to-isoDGR rearrange-
ment NGR-peptides are able to bind to both CD13 and RGD binding integrin, which is why
these peptides are considered ideal candidates for selective, dual acting, tumor targeting
ligands (Fig 1).
Several NGR-containing peptide sequences have been identified and optimized through
phage-display libraries. Nevertheless, only a few NGR peptides have been exploited for their
specific dual tumor and tumor vessel homing ability [10,11]. There are examples for both lin-
ear and cyclic NGR peptides, but as a general rule, small cyclic NGR peptides are superior
compared to their linear forms in terms of selectivity [12–14]. The increased efficiency due to
cyclization is a common phenomenon and many examples are known, where conformational
constraining led to improved affinity [15]. At present, the two widely used effective and tumor
selective cyclic NGR peptides are [CNGRC] [10] and [KNGRE]-NH2 [11].
The disulfide bridge containing [CNGRC] was applied for targeted delivery of various che-
motherapeutic drugs (e.g. Pt-complex, doxorubicin) [16,17], viral particles [18], proapoptotic
peptides [19], radioisotopes [20], cytokines [21–25] and siRNA [26]. Anthracyclines can also
inhibit cell growth through antiangiogenic pathways [27,28]. Therefore, anthracycline–NGR
Fig 1. Rearrangement of NGR peptides resulting in dual acting properties.
https://doi.org/10.1371/journal.pone.0178632.g001
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peptide-based conjugates are excellent candidates for vascular endothelium targeted tumor
therapy. Dox-[CNGRG] conjugate showed antitumor effect both in vitro and in vivo, but no
significant selectivity between CD13 positive and negative tumor cells/tissues was observed
[17,29]. However, this version of cyclic NGR was formed by using a labile disulfide bridge
between the flanking cysteines, which may complicate the synthesis of derivatives and
conjugates.
As a more stable alternative of [CNGRC] intended for wider applications, Negussie et al.
designed the “head-to-side chain” amide bond cyclized [KNGRE]-NH2 peptide [12]. Although
this peptide is identical in terms of cycle size (17 atoms), the NGR motif showed increased sta-
bility. Because of this characteristic, [KNGRE]-NH2 has been studied for tumor targeting
applications, for delivery of liposomes [12], fluorescent dyes [12,30] and radioisotopes for PET
imaging [31].
In our previous study we developed small cyclic NGR peptides containing a thioether bond
and compared their chemostability [32]. Based on these results, in the present study our aim
was to (i) design and synthesize novel cyclic NGR peptide-drug conjugates; (ii) follow and
characterize the rate of succinimide formation and the rearrangement of the conjugates; (iii)
measure their cytotoxic effect in vitro; and (iv) understand the structure-biological activity
relationship of the conjugates, in hope of creating effective NGR-based drug delivery systems
as chemotherapeutics for tumor targeting.
Materials and methods
All reagents and solvents (anhydrous) were obtained from VWR International Kft. (Debrecen,
Hungary). Fmoc-Rink Amide MBHA resin, N,N0-diisopropylcarbodiimide (DIC), 1,8-diazabi-
cyclo[5.4.0]undec-7-ene (DBU), 1-hydroxybenzotriazole hydrate (HOBt), and ninhydrin were
purchased from Sigma-Aldrich Kft (Budapest, Hungary). Fmoc-Rink Amide 2CT resin and all
amino acid derivatives used in this study were purchased either from Merck KGaA (Darm-
stadt, Germany) or Iris Biotech GmbH (Marktredwitz, Germany).
Preparation of isopropylidene protected aminooxyacetic acid
Aminooxyacetic acid (0.7 g (7.7 mmol) (O-carboxymethyl)hydroxylamine)) was dissolved in
25 mL technical grade acetone and was allowed to react for 30 minutes, followed by evapora-
tion of the excess of acetone. The remaining oily product was solidified with diethyl ether.
After removal of ether the white crystals were dried in vacuo overnight. The product (0.89 g,
yield: 94%) was identified by ESI-MS and NMR (S1 Fig).
Solid phase synthesis of branched precursor NGR/DGR peptides
The branched NGR and DGR peptides were synthesized manually on Fmoc-Rink Amide
MBHA resin (0.71 mmol/g loading capacity) using standard protecting schemes except for the
synthesis of the KDGRE derivative. In this case the highly acid-labile Fmoc-Rink Amide 2CT
resin (0.67 mmol/g loading capacity) and O-2-PhiPr (2-phenylisopropyl ester) side chain pro-
tecting group for Glu were used. The applied lysine derivatives were Fmoc-Lys(Dde)-OH,
Dde-Lys(Fmoc)-OH and Boc-Lys(Fmoc)-OH depending on their position in the peptide
sequences. The protocol of the modified Fmoc/tBu strategy was as follows: (i) DMF washing (4
x 0.5 min), (ii) Fmoc deprotection with 2% DBU, 2% piperidine, 0.1 M HOBt in DMF (2 x 2
min, 2 x 5 min, 2 x 10 min), (iii) DMF washing (10 x 0.5 min), (iv) coupling of Fmoc-protected
amino acid derivative: DIC: HOBt in DMF (3 equiv each) (1 x 60 min), (v) DMF washing (3 x
0.5 min), (vi) DCM washing (2 x 0.5 min), (vii) ninhydrin assay. The cleavage of Dde protect-
ing group to form the branches was carried out in 2% hydrazine in DMF for 6 x 3 min. The
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standard DIC/HOBt coupling method was used for the incorporation of isopropylidene pro-
tected aminooxyacetic acid to the N-terminus of GFLG spacer sequence in all cases.
The peptide-loaded resins were stirred for 3 h at RT in 10 mL of cleavage mixture (95%
TFA, 2.5% triisopropylsilane (TIS), 2.5% H2O) for the removal of peptides from the resins and
deprotection of the side chains, except for the KDGRE control peptide. The crude products
were precipitated with ice cold diethyl ether and centrifuged for 4 min at 4000 rpm. After
washing three times with diethyl ether, the crude products were dissolved in water and the
solution was purified by RP-HPLC and lyophilized. The cleavage of precursor for control pep-
tide with KDGRE sequence from the resin and removal of the O-2-PhiPr side chain protecting
group occurred in 10 mL of 2% TFA, 2%TIS/DCM for 2 h at RT. After separation from the
resin beads the cleavage mixtures were evaporated and the remaining semi-protected product
was precipitated with d.i. water, collected by centrifugation (4 min at 4000 rpm), dissolved in
acetonitrile-water and lyophilized.
Cyclization of precursor peptides
The thioether linkage and disulfide bridge were formed in 0.1 M TRIS buffer (pH 8.1) at a pep-
tide concentration of 1 mg/mL for 1 h. The mixtures were then adjusted to pH 7 with TFA and
purified by RP-HPLC and lyophilized.
In the case of the amide bond formation salt exchange was performed using 10 equiv of pyr-
idinium hydrochloride in 5 mL MeOH. After 20 min MeOH was evaporated and the remain-
ing oily products were dissolved in DMF at a concentration of 1 mg/mL and BOP, HOBt and
DIPEA (3:3:6 equiv) were added to the solution. The mixtures were stirred for overnight and
then the DMF was evaporated. The oily products were dissolved in acetonitrile-water and
purified by RP-HPLC and the collected fractions were lyophilized. The remaining side chain
protecting groups were cleaved according to the standard protocols before the drug conjuga-
tion procedure, as described above.
Conjugation of daunomycin to cyclic NGR/DGR peptides
Prior to the conjugation of daunomycin (Dau) the isopropylidene protecting group was removed
with 1 M solution of methoxyamine in 0.2 M NH4OAc solution (pH 5). The peptides were dis-
solved in 1 mg/mL concentration, stirred at RT for one hour and were purified by RP-HPLC.
The solvent was evaporated from the collected fractions and the conjugations were carried out in
solution at once. The cyclic, deprotected peptides were dissolved in 0.2 M NH4OAc solution (pH
5.0) at a 10 mg/mL concentration, and 1.5 equiv of Dau was added. The mixtures were stirred
overnight then they were purified by RP-HPLC and lyophilized. The resulting conjugates were
characterized by electrospray ionization mass spectroscopy (ESI-MS).
Reverse phase high performance liquid chromatography (RP-HPLC)
The crude peptides and conjugates were purified on a KNAUER 2501 HPLC system (KNAUER,
Bad Homburg, Germany) using a semi-preparative Phenomenex Jupiter Proteo C18 column
(250 mm x 10.0 mm) with 10 μm silica (90 Å pore size) (Torrance, CA). Linear gradient elution
(0 min 5% B; 65 min 90% B) with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in
MeCN-H2O (80:20, v/v)) was used at a flow rate of 4 mL/min. Peaks were detected at 220 nm.
Analytical RP-HPLC was performed on the same instrument using a Phenomenex Aeris Pep-
tide XB-C18 column (250 mm x 4.6 mm) with 3.6 μm silica as a stationary phase. Linear gradi-
ent elution (0 min 0% B; 5 min 0% B; 50 min 90% B) using the same eluents was applied at a
flow rate of 1 mL/min. Peaks were detected at 220 nm.
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Electrospray ionization mass spectrometry (ESI-MS)
ESI-MS analyses were carried out on an Esquire 3000+ ion trap mass spectrometer (Bruker
Daltonics, Bremen, Germany). Spectra were acquired in the 50–2000 m/z range. Samples were
dissolved in a mixture of 20% acetonitrile and 80% water.
Chemostability measurements
For the stability studies the conjugates were dissolved in DMSO (2% of the final volume), then
10% FBS (fetal bovine serum) containing complete cell culture medium (DMEM CM) was
added up to the 1 mg/mL final concentration of the conjugates followed by incubation at
37˚C. Samples were taken from the mixtures at 0 h, 6 h and after 72 h, respectively, and com-
ponents were separated with Amicon Ultra Centrifugal Filters (cut off 10K, Millipore) in two
steps: (i) The membranes were preconditioned with eluent A (used for HPLC), then samples
diluted with eluent A were added (final volume was 0.5 mL) and centrifuged at 13000 rpm for
15 min and was repeated three times with each sample. Due to daunomycin adsorption ability,
only the small molecules of the cell medium eluted at this stage. (ii) In the next step, eluent B
(used for HPLC) was added (final volume was 0.5 mL) and centrifuged at 13000 rpm for 15
min, followed by lyophilisation to concentrate the samples.
Cell lines and culture conditions
The HT-1080 fibrosarcoma cell line was a kind gift from Dr. Jo´zsef To´va´ri (National Institute
of Oncology, Hungary), the HT-29 human colon cancer cell line was obtained from DCTD
Tumor Repository (NCI at Frederick, Maryland). HT-1080 and HT-29 cells were maintained
in DMEM and RPMI (Sigma Aldrich), respectively, supplemented with 10% FBS, 5 mmol/L
glutamine, and 50 units/mL penicillin and streptomycin (Life Technologies). All cell lines
were cultivated at 37˚C, 5% CO2. Cells were periodically tested and resulted negative for myco-
plasma contamination with the MycoAlert™ mycoplasma detection kit (Lonza, Hungary).
Detection of CD13 receptors on tumor cells by flow cytometry
The surface expression of CD13 was determined with a FITC-conjugated OKM13 monoclo-
nal murine antibody (Ortho Diagnostic systems). Briefly, 250,000 cells (in suspension) were
stained with 5 μL of the FITC-conjugated OKM13 for 30 min at 37˚C. After the incubation,
cells were washed with PBS and 1 μL PI solution was added to distinguish live/dead cells.
Samples were measured and analyzed with an Attune1 Acoustic Focusing Cytometer (Life
Technologies).
In vitro cytostatic effect and cytotoxicity
Cells were seeded in 5000 cells/well density in 100 μL medium, and were incubated overnight. The
following day 100 μL of serially diluted drugs were added to the cells. In the case of the cytostatic
effect measurements, drug containing medium was gently removed from the plates after 6h incuba-
tion, fresh medium was added to each wells, and the plates were further incubated for additional 66
h (72 h in total). In the case of cytotoxicity measurements, the drug containing medium was on the
cells for the full period of the 72 h assay. At 72 h, supernatant was removed from the cells, and viabil-
ity was assessed by the PrestoBlue1 reagent (Life Technologies), which was diluted in PBS to reach
the concentration given in the manufacturer’s instruction. Curves were fitted by GraphPad Prism 5
software using the sigmoidal dose–response model (https://www.graphpad.com/scientific-software/
prism/). The conjugates were serially diluted, 9 concentrations were measured in triplicates. The
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tests were carried out 3–4 times; IC50 values were averaged; statistical significance was calculated
using unpaired t-tests.
Lysosomal degradation
Rat liver lysosomal homogenate was prepared as described previously [33]. Protein concentra-
tion was determined with bicinchoninic acid (Pierce BCA protein assay) according to the
manufacturer’s protocol (ThermoFisher Scientific, Rockford, IL, USA) and it was 17.4 μg/μL.
Degradation of the bioconjugates in the rat liver lysosomal homogenate was determined as fol-
lows: i) bioconjugates were dissolved in d.i. water at a concentration of 4 μg/μL, ii) the solutes
were further diluted to a concentration of 0.2 μg/μL with 0.2 M NaOAc (pH 5.0), iii) the rat
liver lysosomal homogenate was diluted with 0.2 M NaOAc (pH 5.0) to a concentration of
3.48 μg/μL, iv) the homogenate was added to the conjugates (conjugate/lysosomal homogenate
ratio = 1:1, w/w), v) the reaction mixtures were incubated at 37˚C and aliquots of 13 μL were
taken at 5 min, 6 h and 72 h, vi) the reactions were quenched by adding 2 μL of formic acid,
followed by LC-MS analysis (Bruker Esquire 3000+; Jasco PU-2085plus system; Supelco
Ascentis C18 coloum, 3 μm, 2,1 x 150 mm, 100 Å).
Cellular uptake
HT-1080 and HT-29 cells were seeded at a 250,000 cells/well density, and were incubated over-
night in their culturing media. The following day daunomycin conjugates were dissolved in
culturing media (FBS supplemented), and added to the cells immediately at 10 μM final con-
centration. After 6 h incubation at 37˚C the supernatant was removed, cells were washed with
PBS and trypsinized with 0.1% trypsin (Gibco1 by Life Technologies) for 10 minutes. Trypsi-
nization was terminated with FBS containing medium, then cells were washed and suspended
in serum free medium. For live/dead distinction we used Zombie Violet reagent (BioLegend,
San Diego, CA). Samples were measured and analyzed with an Attune1 Acoustic Focusing
Cytometer (ThermoFisher Scientific).
Results and discussion
Cyclic NGR peptides are promising candidates as targeting moieties for drug delivery to
CD13-positive tumor cells and the tumor neovasculature. Up to now the most widely used
NGR peptide conjugates have been based on the disulfide bridge containing cyclic peptide
[CNGRC]. The cargo (including tumor necrosis factor (TNF), platina complexes, etc.) is usu-
ally attached to the C-terminus of the peptide [17,24]. Recently, an amide bond containing
cyclic NGR peptide ([KNGRE]-NH2) with higher resilience against deamidation has been
described, in which cargos such as fluorescent labels or chelated 68Ga for PET were attached to
the lysine side chain [12,31]. Several cyclic NGR peptides with thioether linkage were devel-
oped in our laboratory [32]. Compared to the amide bond or the disulfide bridge, the enzyme
stability of the thioether linkage is significantly higher and it can be formed more easily [34].
Conversely, it was suggested that the conjugates with thioether linkage have a lower chemost-
ability to deamidation compared to the previously mentioned disulfide and amide bond con-
taining versions [32]. However, deamidation is highly influenced by the structure of cyclic
peptides. The extremely labile cyclic peptides produce isoaspartyl derivatives, which may be
useful in a dual targeting approach in which the attached drugs are delivered to both CD13
receptor and the RGD-binding integrins. Based on our previous study we selected four cyclic
NGR peptides for drug targeting: ([KNGRE]-NH2, Ac-[CNGRC]-NH2, [CH2-CO-NGRC]-
NH2, [CH2-CO-KNGRC]-NH2) representing stable, moderately and two highly labile
thioether bond-containing compounds, respectively [32]. The cyclic NGR peptides were
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attached to daunomycin (Dau) with good yield via oxime bond formation [35]. In contrast to
ester linked doxorubicin [17,29] the oxime linkage results in a conjugate which is stable in
human plasma. Although the free drug is not released from the oxime linkage [33], conjugates
show higher tumor growth inhibition and antiangiogenic effect in vivo compared to the free
drug used at MTD [36]. In addition, this approach is a cost effective and useful method for
searching appropriate homing peptides following the development of other drug–peptide con-
jugates [37]. Therefore, Dau was linked to the cyclic NGR peptides via oxime linkage using
aminooxyacetic acid (Aoa) attached to a Cathepsin B labile GFLG tetrapeptide spacer to ensure
efficient drug release. The lysosomal enzyme Cathepsin B is highly upregulated in various can-
cer cells, which results in the selective release of the free drug or its active metabolite in tumors
(Dau = Aoa-Gly-OH as the smallest metabolite in these cases). The Dau = Aoa-GFLG part of
the molecule was connected directly to the side chain of Lys in the cycle or to the C-terminus
of the cyclic peptide through an additional Lys. The C-terminal elongated variants were
extended with two glycine residues to prevent incidental structure-based reduction of effi-
ciency. Six novel NGR peptide–Dau conjugates were developed (Fig 2) and their stability, lyso-
somal degradation, cellular uptake as well as cytostatic/cytotoxic effects were measured. In
addition, the conjugates in which Asn was replaced by Asp were also prepared as controls to
allow the identification of the deamidated compounds in stability studies.
Synthesis of cyclic NGR peptide-Dau conjugates
Linear precursor peptides were prepared on Fmoc-Rink Amide MBHA or Fmoc-Rink Amide
2CT resins using Fmoc/tBu strategy. Through the syntheses a modified Fmoc cleavage mixture
and protocol was used to hinder undesirable succinimide ring formation.
In cases of conjugates 1, 2, 3, 5, the enzyme labile spacer with isopropylidene protected
amoniooxyacetyl moiety was built up using a Fmoc-Lys(Dde)-OH, as the C-terminal amino
Fig 2. Structure of the cyclic NGR peptides and their Dau conjugates.
https://doi.org/10.1371/journal.pone.0178632.g002
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acid derivative (Fig 3). The isopropylidene protected aminooxy moiety (S1 Fig) is stable under
the conditions applied for the synthesis and cleavage from the resin. The second step was the
removal of the Dde as lysine side chain protecting group, followed by coupling two glycine res-
idues and the specified NGR moieties. Peptide 5 contains Boc-Lys(Fmoc) in the KNGRE
sequence, which allowed the selective “head-to-side chain” cyclization after the cleavage of the
semi-protected peptide from the resin.
Synthesis of branched conjugates 4 and 6 was performed in a reverse order: first the NGR
sequences were prepared with incorporation of Dde-Lys(Fmoc)-OH (conjugate 4) and Boc-Lys
(Fmoc)-OH (conjugate 6) (Fig 4). Next, the Fmoc side chain protecting group was removed,
which allowed the synthesis of isopropylidene protected Aoa-GFLG spacer on the ε-amino
group of Lys.
Fig 3. Synthesis of Dau-NGR peptide conjugates with disulfide bridge or thioether bond in the cycle.
https://doi.org/10.1371/journal.pone.0178632.g003
Fig 4. Synthesis of Dau-NGR peptide conjugates with amide bond in the cycle.
https://doi.org/10.1371/journal.pone.0178632.g004
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For the development of cyclic NGR peptides via thioether linkage (conjugate 1, 3 and 4) an
additional chloroacetyl group was incorporated to the N-terminus of the NGR sequence at the
last step using chloroacetic acid pentachlorophenyl ester.
The synthetic protocol of the control DGR derivatives of 1, 2, 3, 4 was the same for the
NGR peptides (Fig 3), except that Fmoc-Asp(OtBu)-OH was used instead of Fmoc-Asn(Trt)-
OH. Because DGR derivatives of compound 5 and 6 contain both Asp and Glu, a different syn-
thetic route was needed (Fig 5). For this purpose, the highly acid sensitive Fmoc-Rink Amide
2CT resin and the highly acid sensitive Fmoc-Glu(OPp)-OH amino acid derivative were
applied for selective removal that allow “head-to-side chain” cyclization. In each case the cycli-
zation was carried out in TRIS buffer (pH 8.1) for thioether linkage (for 3 h) and disulfide
bond formation (air oxidation for overnight) or in DMF in the presence of BOP/HOBt/
DIPEA for amide bond formation. Removal of isopropylidene protection from aminooxyace-
tyl moiety and Dau conjugation was achieved in an NH4OAc solution (pH 5.0), as shown in
Figs 3–5.
The analytical characteristics of the cyclic NGR peptide-drug conjugates are summarized in
Fig 6. (The HPLC chromatograms and the mass spectra of the purified cyclic peptides are pre-
sented in Supporting Information (S2–S7 Figs). Purity of the cyclic peptides was over 95% in
all cases.
Chemostability measurements of cyclic NGR peptide-Dau conjugates
The stability of cyclic NGR peptide-drug conjugates was determined in DMEM cell culture
medium containing 10% FBS (fetal bovine serum), under conditions mimicking in vitro cyto-
toxicity experiments (incubation at 37˚C). Samples for dialysis were taken at 6 h and 72h.
Except deamidation no other decomposition of the compounds was observed during the incu-
bation time. The deamidation rate was followed by analytical RP-HPLC and was calculated
from the area under the curve (AUC). The compounds were identified by both mass spectro-
metric analyses and by the HPLC retention time of the reference DGR peptide conjugates. The
results of chemostability measurements are summarized in Fig 7, chromatograms are pre-
sented in the Supporting Information (S2–S7 Figs).
Fig 5. Synthesis of the control Dau-DGR peptide conjugates with amide bond in the cycle.
https://doi.org/10.1371/journal.pone.0178632.g005
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Fig 6. Characteristics of cyclic NGR peptide–daunomycin conjugates. aHPLC column: Phenomenex
AERIS Peptide 3,6 μm XB-C18 (250 x 4,6 mm); eluents 0.1% TFA/ water (A) and 0.1% TFA/CH3CN−water
(80:20 v/v) (B); gradient 0 min 0% B, 5 min 0% B, 50 min 90% B; flow rate 1 mL/min; detection: 220 nm.
bAverage molecular weight. cESI-MS: Bruker Daltonics Esquire 3000+ ion trap mass spectrometer.
https://doi.org/10.1371/journal.pone.0178632.g006
Fig 7. Chemostability of cyclic NGR peptide–daunomycin conjugates.
https://doi.org/10.1371/journal.pone.0178632.g007
Dual targeted tumor therapy
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The results showed that the stability characteristics of the conjugates were similar to those
observed for non-conjugated small cyclic NGR peptide derivatives in an earlier study [32].
Decomposition of the thioether bond containing cyclic peptide conjugates (1, 3 and 4) was
faster as compared to the disulfide (2) and amide bond (6 and 5) containing conjugates. Inter-
estingly, the amide and thioether bond containing conjugates showed different stability
depending on the conjugation site. Lower stability was observed in case of the amide bond
containing conjugate 6, in which the drug-spacer element was attached directly to the side
chain of Lys, compared to the conjugate 5. In contrast, conjugates containing a thioether link-
age in the cycle showed faster deamidation when the drug-spacer moiety was attached to the
C-terminus of the cyclic peptide. The most stable compound was conjugate 5 that did not
decompose at all during the time of measurement. Furthermore, it seems that during the time
frame of the experiment, decomposition of 2 and 6 resulted only in Asp derivatives without
any isoAsp formation under the examined conditions. This observation contradicts the results
of the previous study on unconjugated cyclic NGR peptides [32], which suggested that the
direction of the decomposition is influenced by the drug-spacer moiety. These results suggest
that the decomposition of the conjugates cannot be predicted from results obtained with the
free cyclic peptide. The isoAsp/Asp ratio after deamidation of conjugates 1, 3 and 4 in DMEM
was about the same (~ 2:1) as observed with the free peptides. In conclusion, the stability data
suggest that the thioether bond containing cyclic NGR peptides might be good candidates for
dual targeting to both CD13 and RGD integrin receptors.
Cytostatic/cytotoxic effects of NGR-peptide-Dau conjugates
The cytostatic/cytotoxic effect of the cyclic NGR peptide-Dau conjugates was examined in vitro
on CD13-positive HT-1080 human fibrosarcoma cells and on CD13-negative HT-29 human
colon adenocarcinoma cells. High expression of CD13 in HT-1080 cells was confirmed by
FACS, using the CD13-specific OKM13 antibody. In contrast, HT-29 cells do not express any
CD13 (S8 Fig). Since both type of cells express RGD integrin receptors [38], but only HT-1080
cells express CD13 receptors, a comparative study of these cells allows the analysis of structure-
activity relationship and selectivity. Since several integrin receptors (e.g. αvβ3, αvβ5, αvβ6, α5β1)
can recognize isoDGR peptides [39,40], expression of any specific integrin receptors was not
investigated. We compared the toxicity of the conjugates and the free drug molecules. It is
important to note that the free drug enters the cell via diffusion, while the conjugates are taken
up by a receptor-mediated pathway, which is followed by the intracellular release of the drug
molecule or its active metabolite. Therefore, the in vitro toxicity of oxime-linked drug conjugates
is expected to be inferior to that of the free drug as indicated by our previous studies [35, 41]. In
our first experiment the cells were treated for 6 h with the conjugates, then the cells were washed
and incubated for another 66 h (cytostatic effect). In the second experiment the conjugates were
added to the cells for 72 h (cytotoxic effect). The IC50 values are summarized in Fig 8.
As expected, free daunomycin was equally toxic to the cells. Conjugate 1, containing the
least stable ring did not show any cytostatic effect in the concentration range measured. After
72 h, a slight increase of the cytotoxic effect was observed, which was more pronounced on
HT-29 cells. This unique behaviour suggests that conjugate 1 might internalize via integrin
receptors after the formation of the isoAsp derivative. Conjugate 1 has a cyclic NGR part with
a 15-membered ring in contrast with the other compounds having 17- or 18-membered rings
in their structure. Therefore, it might be concluded that this small ring size does not allow
appropriate receptor binding to CD13.
In contrast, conjugate 2 (containing a disulfide bridge) showed preferential toxicity to HT-
1080 cells in the cytostatic experiments, resulting in the highest selectivity. The antitumor
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effect of 2 increased in time (72 h treatment), but its selectivity decreased significantly. In com-
parison to conjugates 3 (thioether linkage) and 5 (amide bond), both containing free Lys in
the cycle, conjugate 5 had slightly better activity against HT-1080 cells. However, the selectivity
of conjugate 5 to CD13 receptors (as judged by the relative toxicity against the two cell lines)
was not significant after 6 h treatment, whereas it was significantly more toxic to HT-1080
cells in the 72 h experiment. This can also be explained by its higher chemostability that results
in longer exposure the cells to the unmodified NGR peptide–drug conjugate. In contrast, their
analogs in which the drug molecule is connected to the side chain of Lys in the cycle (conju-
gates 4 and 6) were more specific but less toxic, especially in the cytotoxicity experiments.
Interestingly, there was no correlation between the specificity and the chemostability of the
conjugates. To better understand the observed differences in the cytostatic/cytotoxic effects,
lysosomal degradation and cellular uptake of the conjugates were studied.
Lysosomal degradation
Conjugates for drug targeting with receptor-binding peptides may enter the cells by receptor
mediated endocytosis. Endocytic vesicles fuse with lysosomes, which is followed by the degra-
dation of the conjugates by lysosomal enzymes. Cathepsin B is one of the main lysosomal
enzymes overexpressed in cancer cells. Therefore, Cathepsin B labile spacers (e.g. GFLG tetra-
peptide) are often incorporated between the drug and targeting moiety [41]. We used a rat
lysosomal homogenate to study the degradation of conjugates and to follow the release of drug
containing metabolites (Fig 9, S9–S14 Figs). The results indicated that conjugates 1, 3 and 5
decomposed within 6 h. The main Dau containing metabolite was Dau = Aoa-Gly-OH that
binds efficiently to DNA [35]. In addition, a minor peak corresponding to Dau = Aoa-Gly-
Phe-OH could also be detected. The peak corresponding to Dau = Aoa-GF-OH was the high-
est in case of conjugate 1. In contrast to these conjugates, decomposition of the disulfide bond
Fig 8. Cytostatic/cytotoxic effect of cyclic NGR peptide–daunomycin conjugates. aTests were carried
out 4 times; btests were carried out 3 times; IC50 values were averaged; statistical significance was calculated
using unpaired t-tests.
https://doi.org/10.1371/journal.pone.0178632.g008
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containing conjugate (2) was much slower. After 6 h the presence of the starting compound
could be detected and the peak of Dau = Aoa-Gly-Phe-OH was also high. This slow degrada-
tion might be one of the reasons why conjugate 2 is less toxic than conjugate 5, which has the
same ring size. Interestingly, branching conjugates 4 and 6 decomposed very slowly probably
because of steric hindrance. After 6 h incubation the main components were still the intact
conjugates 4 and 6, which might have weak binding activity to DNA, explaining the low toxic-
ity of these conjugates. After 72 h only Dau = Aoa-Gly-OH could be detected in cases of all
conjugates.
Cellular uptake
As daunomycin-conjugates are fluorescent, we were able to follow their cellular uptake with
a flow cytometer (Fig 10, S15 Fig). Conjugates 2 and 5 (both having 17-atom ring size in
NGR peptide) showed higher accumulation after 6 h incubation than the other conjugates,
in accordance with their higher activity in the cytostatic experiments. Significantly, conju-
gate 2, which was selective in the short term cytostatic experiments, showed higer accumu-
latoin in HT-1080 cells. The higher uptake of 2 compared to 5 might partly compensate its
slower degradation resulting in almost similar bioactivity. Conjugate 3 showed a moderate
uptake that was a bit more pronounced in HT-29 cells. We speculate that the high cytostatic
effect of 3 is explained by its fast decomposition resulting in the active Dau = Aoa-Gly-OH
metabolite. Conjugate 1 did not show significant cellular uptake. This observation suggests
that conjugate 1 has no affinity to CD13 receptors. However, after deamidation the formed
isoDGR might be recognized by RGD integrin receptor, that results in moderate cytotoxic-
ity in both cell lines during a longer treatment. Conjugates 4 and 6 showed low cellular
uptake by both types of cell during the 6 h treatment. Taking also the slow metabolite release
into account, this observation explains the lack of significant cytostatic effect.
Fig 9. Lysosomal degradation of daunomycin-conjugates after 6 h.
https://doi.org/10.1371/journal.pone.0178632.g009
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Conclusions
Six new cyclic NGR peptide–daunomycin conjugates were prepared with different structure in
terms of conjugation sites and applied linkage in the cycle. Chemostability (deamidation of
Asn) of the conjugates and the free cyclic peptides [32] was found to be different. However, in
most cases no correlation between the chemostability and selectivity or dual acting effect of
conjugates could be identified. Therefore, further experiments are needed to analyse the bind-
ing affinity of conjugates to different receptors. Nevertheless, we can conclude that the conju-
gates in which the drug molecule is attached through C-terminal elongation of cyclic NGR
peptides (conjugates 2, 3, 5) have higher antitumor activity against both cell lines, irrespec-
tively of the bond in the cycle, as compared to branched conjugates 4 and 6. Conjugates 4 and
6 showed higher selectivity to HT-1080 cells. Therefore, conjugates 2, 3 and 5 are suitable for
dual targeting while conjugates 4 and 6 can be used for selective CD13 targeting. We also find
that the antitumor activity of the NGR peptide–drug conjugates depends on complex mecha-
nisms including cellular uptake, enzyme degradation and NGR-isoDGR rearrangement. In
addition, conjugates 2, 3 and 5 showed similar antitumor activity against HT-29 cells in vitro
as the previously prepared GnRH-III–Dau conjugate [42] that had significant and better in
vivo tumor growth inhibition effect compared to the free drug [36]. These results warrant the
study of the in vivo antitumor effect of the most active NGR–Dau conjugates alone, or in com-
bination with the GnRH–drug conjugate.
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S1 Fig. Charactheristics of isopropylidene protected aminooxyacetic acid. 1H and 13C
NMR spectra were recorded on a Bruker-Avance 200 MHz spectrometer in DMSO-d6 at
room temperature (303 K). Chemical shifts (δ) are given in parts per million (ppm) units rela-
tively to the internal standard TMS (δ = 0.00 for 1 H, δ = 0.00 for 13C). 1H NMR (200 MHz,
DMSO-d6): δ 4.42 (s, 2H, CH2), 1.80 (s, 3H, CH3), 1.77 (s, 3H CH3);
13C NMR (62,9 MHz,
DMSO-d6) δ 172.34, 156.39, 70.58, 22.14, 16.46 ppm.
(PDF)
Fig 10. Direct uptake of daunomycin-conjugates. Normalized uptake values indicate the fold increase of
the measured fluorescent units compared to the autofluorescence of empty cells.
https://doi.org/10.1371/journal.pone.0178632.g010
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S2 Fig. Chemostability and Asp control of Dau = GFLGK([CH2CO-NGRC]GG)-NH2 (1).
(PDF)
S3 Fig. Chemostability and Asp control of Dau = GFLGK(Ac-[CNGRC]GG)-NH2 (2).
(PDF)
S4 Fig. Chemostability and Asp control of Dau = GFLGK([CH2CO-KNGRC]GG)-NH2 (3).
(PDF)
S5 Fig. Chemostability and Asp control of [CH2CO-K(Dau = Aoa-GFLG)NGRC]-NH2 (4).
(PDF)
S6 Fig. Chemostability and Asp control of Dau = GFLGK([KNGRE]GG)-NH2 (5).
(PDF)
S7 Fig. Chemostability and Asp control of [K(Dau = Aoa-GFLG)NGRE]-NH2 (6).
(PDF)
S8 Fig. Characterization of CD13 expression by flow cytometry. Expression of CD13 in
HT1080 (A) and HT-29 cells (B). Expression was followed using the FITC-conjugated
CD13-specific OKM13 antibody (black); red histograms represent the isotype control.
(PDF)
S9 Fig. Lysosomal degradation of Dau = GFLGK([CH2CO-NGRC]GG)-NH2 (1).
(PDF)
S10 Fig. Lysosomal degradation of Dau = GFLGK(Ac-[CNGRC]GG)-NH2 (2).
(PDF)
S11 Fig. Lysosomal degradation of D au = GFLGK([CH2CO-KNGRC]GG)-NH2 (3).
(PDF)
S12 Fig. Lysosomal degradation of [CH2CO-K(Dau = Aoa-GFLG)NGRC]-NH2 (4).
(PDF)
S13 Fig. Lysosomal degradation of Dau = GFLGK([KNGRE]GG)-NH2 (5).
(PDF)
S14 Fig. Lysosomal degradation of [K(Dau = Aoa-GFLG)NGRE]-NH2 (6).
(PDF)
S15 Fig. Cell uptake measurements with FACS. Accumulation of daunomycin-conjugates in
(A) HT1080 and in (B) HT29 cells. Uptake of compound 1 (yellow); 2 (red); 3 (light green); 4
(dark green); 5 (purple); 6 (light blue). Empty control (the autofluorescence of the cells) is indi-
cated with dark blue. Side scatter versus forward scatter values for (C) HT1080 and for (D)
HT29 cells.
(PDF)
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